Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mage-tarm symptomer og toleranse hos spedbarn som mates med spedbarnsformel basert på geite- eller kumelk (MESK-2)

13. november 2026 oppdatert av: Ausnutria Hyproca B.V.

Effekten av en geitemelkbasert barneformel på gastrointestinale symptomer og tolerabilitet hos friske fullgångne spedbarn: en dobbeltblind randomisert kontrollert studie

This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

144

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Riyadh, Saudi-Arabia
        • Rekruttering
        • King Faissal Specialist Hospital & Research Centre
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 uker til 2 måneder (Barn)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age between 14 days and 90 days.
  • Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.
  • Infants who have received CMF for at least 7 consecutive days.
  • Exclusive formula feeding.
  • Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and <10.
  • Parents' or caregivers, aged ≥18 years, willing to give informed consent and adhere to study protocol

Exclusion Criteria:

  • Exclusively or partially feeding with human milk
  • Introduced to solid food, supplementary feeding, use of pre- and/or probiotics as a supplement
  • Congenital or recurrent chronic conditions and/or malabsorption that could interfere with study parameters.
  • Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and/or lactose intolerance.
  • Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)
  • Sibling already participating in this study
  • Participation in another clinical trial

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intervention group

Goat milk-based infant formula

Study product is administered on demand until the age of 6 months.

Aktiv komparator: Control group

Cow's milk-based infant formula

Study product is administered on demand until the age of 6 months.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gastrointestinal symptoms as determined by CoMiSS
Tidsramme: Difference between groups at Day 14 of the intervention

The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

Difference between groups at Day 14 of the intervention
Gastrointestinal tolerance as determined by IGSQ
Tidsramme: Difference between groups at the end of the intervention at 24 weeks

The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

Difference between groups at the end of the intervention at 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gastrointestinal symptoms throughout the study as determined by CoMiSS
Tidsramme: From enrollment to the end of the intervention at 24 weeks

The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

From enrollment to the end of the intervention at 24 weeks
Gastrointestinal tolerance throughout the study as determined by IGSQ
Tidsramme: From enrollment to the end of the intervention at 24 weeks

The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari
Tidsramme: From enrollment to the end of the intervention at 24 weeks

The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score <7 as mild symptoms and score 10 to 20 as severe symptoms.

From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of respiratory infections as determined by CARIFS
Tidsramme: From enrollment to the end of the intervention at 24 weeks

Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment.

From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of ear infections as determined by AOM-SOS V5
Tidsramme: From enrollment to the end of the intervention at 24 weeks

The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions.

From enrollment to the end of the intervention at 24 weeks
Quality of life as determined by PedsQL
Tidsramme: From enrollment to the end of the intervention at 24 weeks

The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100.

From enrollment to the end of the intervention at 24 weeks
Quality of life as determined by WHOQoL-BREF
Tidsramme: From enrollment to the end of the intervention at 24 weeks

The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life.

From enrollment to the end of the intervention at 24 weeks
Weight
Tidsramme: From enrollment to the end of the intervention at 24 weeks

Weight will be measured in kilograms.

From enrollment to the end of the intervention at 24 weeks
Height
Tidsramme: From enrollment to the end of the intervention at 24 weeks

Height will be measured in centimeters.

From enrollment to the end of the intervention at 24 weeks
Head circumference
Tidsramme: From enrollment to the end of the intervention at 24 weeks

Head circumference will be measured in centimeters.

From enrollment to the end of the intervention at 24 weeks
WHO z-scores
Tidsramme: From enrollment to the end of the intervention at 24 weeks

Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length.

From enrollment to the end of the intervention at 24 weeks
Fecal parameters
Tidsramme: Baseline, Day 14, Day 28, Week 12 and Week 24

The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques.

Baseline, Day 14, Day 28, Week 12 and Week 24
Sleep and Crying episodes
Tidsramme: Baseline, Day 14, Day 28, Week 12 and Week 24

Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries.

Baseline, Day 14, Day 28, Week 12 and Week 24
Stool frequency & consistenty
Tidsramme: Baseline, Day 14, Day 28, Week 12 and Week 24

Stool frequency and consistency are recorded for 24 hours prior to visits in diaries.

Baseline, Day 14, Day 28, Week 12 and Week 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. august 2026

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. september 2027

Datoer for studieregistrering

Først innsendt

23. desember 2025

Først innsendt som oppfylte QC-kriteriene

6. januar 2026

Først lagt ut (Faktiske)

15. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • P24-150

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere